Targeting a specific protein to treat lung cancer
Official title: Targeting lysine acetyltransferase MOF/KAT8 in lung cancer
Funded at George Washington University · NIH-10999406 · Data updated 2026-11-12
This study is looking at a protein called MOF/KAT8 to see how it affects lung cancer and how it might help us find new ways to treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $332,355 |
| NIH project number | 5R01CA270149-03 |
| Project ID | NIH-10999406 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung cancer, particularly those with adenocarcinoma.
✕Less likely to help
Patients with non-cancerous conditions or those with lung cancer types not related to the mechanisms being studied may not benefit from this research.
What this research studies
This research investigates the role of the MOF/KAT8 protein in lung cancer, focusing on how it regulates gene expression and cellular processes related to tumor development. By manipulating the acetylation of proteins, the study aims to develop new therapeutic strategies for lung cancer treatment. The research involves both laboratory experiments and mouse models to understand the mechanisms by which MOF influences cancer progression and to explore its potential as a treatment target.
Why it matters
Potential benefit: If successful, this research could lead to new and more effective treatments for lung cancer.
How similar studies have gone: Other research has shown promising results in targeting similar proteins for cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Seto, Edward — George Washington University
- Study coordinator: Seto, Edward
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.